Thalidomide has anti-inflammatory properties in neonatal immune cells

Innate Immunity

Volumn 19, Issue 1, 2013, Pages 42-52

  Puzik, Alexander ^a,b   Thiel, Annette ^c   Faust, Kirstin ^b   Härtel, Christoph ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

apoptosis; interferon; interleukin; Neonate; thalidomide; tumor necrosis factor

Indexed keywords

ASCORBIC ACID; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; PROTEIN BCL 2; RAPAMYCIN; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BLOOD CULTURE; BLOOD SAMPLING; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; LYMPHOCYTE; MONOCYTE; NEWBORN; NORMAL HUMAN; PROTEIN EXPRESSION; SUPERNATANT; TH1 CELL; UMBILICAL CORD BLOOD;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BLOOD CELLS; CELL SEPARATION; CELLS, CULTURED; CYTOKINES; FETAL BLOOD; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT, NEWBORN; INFECTION; PROTO-ONCOGENE PROTEINS C-BCL-2; THALIDOMIDE;

EID: 84872400810     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425912449881     Document Type: Article

References (58)

1. Kenzel S, Henneke P. The innate immune system and its relevance to neonatal sepsis. Curr Opin Infect Dis. 2006 ; 19: 264-270
2. Härtel C, Puzik A, Gopel W, et al. Immunomodulatory effect of vitamin C on intracytoplasmic cytokine production in neonatal cord blood cells. Neonatology. 2007 ; 91: 54-60
3. Schultz C, Rott C, Temming P, et al. Enhanced interleukin-6 and interleukin-8 synthesis in term and preterm infants. Pediatr Res. 2002 ; 51: 317-322
4. Harris MC, D'Angio CT, Gallagher PR, et al. Cytokine elaboration in critically ill infants with bacterial sepsis, necrotizing enterocolitis, or sepsis syndrome: correlation with clinical parameters of inflammation and mortality. J Pediatr. 2005 ; 147: 462-468
5. Naderi N, Pourfathollah AA, Alimoghaddam K, Moazzeni SM. Cord blood dendritic cells prevent the differentiation of naive T-helper cells towards Th1 irrespective of their subtype. Clin Exp Med. 2009 ; 9: 29-36
6. Splawski JB, Lipsky PE. Cytokine regulation of immunoglobulin secretion by neonatal lymphocytes. J Clin Invest. 1991 ; 88: 967-977
7. Tuaeva NO, Abramova ZI, Sofronov VV. The origin of elevated levels of circulating DNA in blood plasma of premature neonates. Ann N Y Acad Sci. 2008 ; 1137: 27-30
8. Wesche DE, Lomas-Neira JL, Perl M, et al. Leukocyte apoptosis and its significance in sepsis and shock. J Leuk Bio. 2005 ; 78: 325-337
9. Unsinger J, Herndon JM, Davis CG, et al. The role of TCR engagement and activation-induced cell death in sepsis-induced T cell apoptosis. J Immunol. 2006 ; 177: 7968-7973
10. Berner R, Niemeyer CM, Leititis JU, et al. Plasma levels and gene expression of granulocyte colony-stimulating factor, tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, IL-8, and soluble intercellular adhesion molecule-1 in neonatal early onset sepsis. Pediatr Res. 1998 ; 44: 469-477
11. Leviton A, Dammann O. Coagulation, inflammation, and the risk of neonatal white matter damage. Pediatr Res. 2004 ; 55: 541-545
12. Hill AV. The genomics and genetics of human infectious disease susceptibility. Annu Rev Genomics Hum Genet. 2001 ; 2: 373-400
13. Von Moos R, Stolz R, Cerny T, Gillessen S. Thalidomide: from tragedy to promise. Swiss Med Wkly. 2003 ; 133: 77-87
14. Corral L, Haslett P, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-a. J Immunol. 1999 ; 163: 380-386
15. Marriott JB, Clarke IA, Dredge K, et al. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4+and CD8+cells. Clin Exp Immunol. 2002 ; 130: 75-84
16. Dredge K, Marriott JB, Dalgleish AG. Immunological effects of thalidomide and its chemical and functional analogs. Crit Rev Immunol. 2002 ; 22: 425-437
17. Schafer PH, Gandhi AK, Loveland MA, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther. 2003 ; 305: 1222-1232
18. Puzik A, Schultz C, Iblher P, et al. Effects of ciclosporin A, tacrolimus and sirolimus on cytokine production in neonatal immune cells. Acta Paediatr. 2007 ; 96: 1483-1489
19. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med. 1997 ; 336: 1487-1493
20. Verbon A, Juffermans NP, Speelman P, et al. A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans. Antimicrob Agents Chemother. 2000 ; 44: 2286-2290
21. Härtel C, Hammers HJ, Schlenke P, et al. Individual variability in cyclosporin A sensitivity: the assessment of functional measures on CD28-mediated costimulation of human whole blood T lymphocytes. J Interferon Cytokine Res. 2003 ; 23: 91-99
22. Härtel C, Schumacher N, Fricke L, et al. Sensitivity of whole-blood T lymphocytes in individual patients to tacrolimus (FK506): impact of interleukin-2 mRNA expression as surrogate measure of immunosuppressive effect. Clin Chem. 2004 ; 50: 141-151
23. Härtel C, Adam N, Strunk T, et al. Cytokine responses correlate differentially with age in infancy and early childhood. Clin Exp Immunol. 2005 ; 142: 446-453
24. Schultz C Cytokines and colony stimulating factors, methods and protocols - Part II: Detection assays for cytokines and growth factors. Methods in molecular biology. Koerholz D Kiess W, ed. Totowa: Humana Press ; 2003: 29-39.
25. Dredge K, Dalgleish AG, Marriott JB. Thalidomide analogs as emerging anti-cancer drugs. Anticancer Drugs. 2003 ; 14: 331-335
26. Haslett PA, Corral L, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8+subset. J Exp Med. 1998 ; 187: 1885-1892
27. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010 ; 24: 22-32
28. Parrino J, Hotchkiss R, Bray M. Prevention of immune cell apoptosis as potential therapeutic strategy for severe infections. Emerg Infect Dis. 2007 ; 13: 191-198
29. Agakidis C, Sarafidis K, Tzimouli V, et al. Antenatal betamethasone does not influence lymphocyte apoptosis in preterm neonates. Am J Perinat. 2009 ; 26: 485-490
30. Chipeta J, Kim Y, Zhang XL, et al. Neonatal (cord blood) T cells can competently raise type 1 and 2 immune responses upon polyclonal activation. Cell Immunol. 2000 ; 205: 110-119
31. Nitsche A, Zhang M, Clauss T, et al. Cytokine profiles of cord and adult blood leukocytes: differences in expression are due to differences in expression and activation of transcription factors. BMC Immunol. 2007 ; 8: 18-18
32. McHugh SM, Rifkin IR, Deighton J, et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol. 1995 ; 99: 160-167
33. Le Blanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004 ; 103: 1787-1790
34. Payvandi F, Wu L, Naziruddin SD, et al. Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1 or NFAT. J Interferon Cytokine Res. 2005 ; 25: 604-616
35. Kaminski BA, Kadereit S, Miller RE, et al. Reduced expression of NFAT-associated genes in UCB versus adult CD4+T lymphocytes during primary stimulation. Blood. 2003 ; 102: 4608-4617
36. Teo S. Properties of Thalidomide and its analogues: Implications for anticancer therapy. AAPS. 2005 ; 7: 14-19
37. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectivly inhibits tumor necrosis facotr alpha production by stimulated human monocytes. J Exp Med. 1991 ; 173: 699-703
38. Rowland TL, McHugh SM, Deighton J, et al. Differential effect of thalidomide and dexamethasone on the transcription factor NF-kappa B. Int Immunopharmacol. 1: 49-61
39. Keifer JA, Guttridge DC, Ashburner BP, et al. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem. 276: 22382-22387
40. Moreira AL, Sampaio EP, Zmuidzina A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993 ; 177: 1675-1680
41. Jimenez JL, Iniguez MA, Munoz-Fernandez MA, et al. Effect of phosphodiesterase 4 inhibitors on NFAT-dependent cyclooxygenase-2 expression in human T lymphocytes. Cell Signal. 2004 ; 16: 1363-1373
42. Nguyen CN, Schnulle PM, Chegini N, et al. Neonatal neutrophils with prolonged survival secrete mediators associated with chronic inflammation. Neonatology. 2010 ; 98: 341-347
43. Davidson D, Miskolci V, Clark DC, et al. Interleukin-10 production after pro-inflammatory stimulation of neutrophils and monocytic cells of the newborn. Comparison to exogenous interleukin-10 and dexamethasone levels needed to inhibit chemokine release. Neonatology. 2007 ; 92: 127-1233
44. Kern JA, Reed JC, Daniele RP, Nowell PC. The role of the accessory cell in mitogen-stimulated human T cell gene expression. J Immunol. 1986 ; 137: 764-769
45. De Groote D, Zangerlea PF, Gevaertb Y, et al. Direct stimulation of cytokines (IL-1beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation. Cytokine. 1992 ; 4: 239-248
46. Wasiluk A, Ratomski K, Wnuczko K, et al. Expression of FasR, Fas-L and Bcl-2 in CD4+and CD8+subpopulations of T lymphocytes in the cord blood of healthy full-term newborns, is gender of influence?. Avd Med Sci. 2009 ; 54: 99-103
47. O'Neill RM, Hassan J, Reen DJ. IL-7-regulated homeostatic maintenance of recent thymic emigrants in association with caspase-mediated cell proliferation and apoptotic cell death. J Immunol. 2003 ; 170: 4524-4531
48. Aggarwal S, Gupta A, Nagata S, et al. Programmed cell death (apoptosis) in cord blood lymphocytes. J Clin Immunol. 1997 ; 17: 63-73
49. Wechsler-Reya RJ, Monroe JG. Lipopolysaccharide prevents apoptosis and induces responsiveness to antigen receptor cross-linking in immature B cells. Immunology. 1996 ; 89: 356-362
50. Fritzsching B, Oberle N, Pauly E, et al. Naive regulatory T cells: a novel subpopulation defined by resistance toward CD95L-mediated cell death. Blood. 2006 ; 108: 3371-3378
51. Morris EJ, Geller HM. Induction of neuronal apoptosis by camptothecine, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity. J Cell Biol. 1996 ; 134: 757-770
52. Lee S, Lee HS, Baek M, et al. MAPK signalling is involved in camptothecin-induced cell death. Mol Cells. 2002 ; 14: 348-354
53. Sampaio EP, Hernandez MO, Carvalho DS, Sarno EN. Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro. Biomed Pharmacother. 2002 ; 56: 13-19
54. Aseffa A, Dietrich MA, Shannon EJ. Effect of thalidomide on apoptosis of lymphocytes and neutrophils. Immunopharmacol Immunotoxicol. 19: 313-326
55. Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+progenitor cells. Cancer Res. 2007 ; 67: 746-755
56. Wiernik PH. Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs). Curr Treat Options Oncol. 2009 ; 10: 1-15
57. Frei-Jones M, McKinstry RC, Perry A, et al. Use of thalidomide to diminish growth velocity in a life-threatening congenital intracranial hemangioma. J Neurosurg Pediatr. 2008 ; 2: 125-129
58. McBride W. Health of thalidomide victims and their progeny. Lancet. 2004 ; 363: 169-169